Literature DB >> 1586067

Nonoccupational beryllium disease masquerading as sarcoidosis: identification by blood lymphocyte proliferative response to beryllium.

L S Newman1, K Kreiss.   

Abstract

Chronic granulomatous lung disease caused by industrial exposure to beryllium continues to occur, but no community cases have been reported in more than 30 yr. With the advent of a blood screening test that detects beryllium sensitization, physicians can discriminate chronic beryllium disease from sarcoidosis. A 56-yr-old woman in whom sarcoidosis was diagnosed had an unremarkable occupational history, but her husband was a beryllium production worker. Blood and bronchoalveolar lavage lymphocyte transformation tests, measuring the beryllium-specific cellular immune response, were abnormal, confirming a diagnosis of chronic beryllium disease. Chronic beryllium disease continues to occur in the nonoccupational setting and among bystanders in industry, masquerading as sarcoidosis. Because even transient or possibly low levels of exposure may cause disease, this case has important implications for how clinicians, industry, and government agencies define the populations at risk of chronic beryllium disease.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1586067     DOI: 10.1164/ajrccm/145.5.1212

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  11 in total

1.  SELDI-TOF derived serum biomarkers failed to differentiate between patients with beryllium sensitisation and patients with chronic beryllium disease.

Authors:  B C Tooker; R P Bowler; J M Orcutt; L A Maier; H M Christensen; L S Newman
Journal:  Occup Environ Med       Date:  2011-01-27       Impact factor: 4.402

Review 2.  Clinical application of beryllium lymphocyte proliferation testing.

Authors:  Barbara P Barna; Daniel A Culver; Belinda Yen-Lieberman; Raed A Dweik; Mary Jane Thomassen
Journal:  Clin Diagn Lab Immunol       Date:  2003-11

3.  CD28 costimulation independence of target organ versus circulating memory antigen-specific CD4+ T cells.

Authors:  Andrew P Fontenot; Laia Gharavi; Sean R Bennett; Scott J Canavera; Lee S Newman; Brian L Kotzin
Journal:  J Clin Invest       Date:  2003-09       Impact factor: 14.808

Review 4.  Linking genetic susceptibility and T cell activation in beryllium-induced disease.

Authors:  Michael T Falta; Natalie A Bowerman; Shaodong Dai; John W Kappler; Andrew P Fontenot
Journal:  Proc Am Thorac Soc       Date:  2010-05

5.  Target organ localization of memory CD4(+) T cells in patients with chronic beryllium disease.

Authors:  Andrew P Fontenot; Scott J Canavera; Laia Gharavi; Lee S Newman; Brian L Kotzin
Journal:  J Clin Invest       Date:  2002-11       Impact factor: 14.808

Review 6.  Significance of the blood beryllium lymphocyte proliferation test.

Authors:  L S Newman
Journal:  Environ Health Perspect       Date:  1996-10       Impact factor: 9.031

7.  CpG promoter methylation status is not a prognostic indicator of gene expression in beryllium challenge.

Authors:  Brian C Tooker; Katherine Ozawa; Lee S Newman
Journal:  J Immunotoxicol       Date:  2015-12-16       Impact factor: 3.000

Review 8.  T cell recognition of beryllium.

Authors:  Shaodong Dai; Michael T Falta; Natalie A Bowerman; Amy S McKee; Andrew P Fontenot
Journal:  Curr Opin Immunol       Date:  2013-08-23       Impact factor: 7.486

9.  Simultaneous testing of immunological sensitization to multiple antigens in sarcoidosis reveals an association with inorganic antigens specifically related to a fibrotic phenotype.

Authors:  E Beijer; R Kraaijvanger; C Roodenburg; J C Grutters; B Meek; M Veltkamp
Journal:  Clin Exp Immunol       Date:  2020-10-06       Impact factor: 4.330

10.  Chronic beryllium disease: uncommon disease, less common diagnosis.

Authors:  D C Middleton
Journal:  Environ Health Perspect       Date:  1998-12       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.